GEROPHARM brings back Ozempic® with a new name: Semavic®

Semavic® (an Ozempic® analogue) has hit the Russian market.

The number of pharmacies where it is available will expand. Diabetes patients will be able to get it under preferential schemes as well.

Semavic® replaced the product that since this year has not been supplied from Denmark to Russia. GEROPHARM has sufficient manufacturing facilities to produce required amounts of the medicinal products while the price will be lower than that of imported analogues.

GEROPHARM also plans to seek opportunities within the law to meet the demand for semaglutide abroad.